Publicações científicas

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

Mishima Y (1), Paiva B (2), Shi J (3), Park J (4), Manier S (5), Takagi S (5), Massoud M (5), Perilla-Glen A (5), Aljawai Y (5), Huynh D (5), Roccaro AM (6), Sacco A (6), Capelletti M (5), Detappe A (5), Alignani D (2), Anderson KC (5), Munshi NC (5), Prosper F (2), Lohr JG (7), Ha G (7), Freeman SS (7), Van Allen EM (4), Adalsteinsson VA (7), Michor F 3, San Miguel JF (2), Ghobrial IM (8).

(1) Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
(2) Clinica Universidad de Navarra, Centro de Investigaciones Medicas Aplicadas (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona 31008, Spain.
(3) Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
(4) Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
(5) Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
(6) Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; ASST Spedali Civili Department Medical Oncology, CREA Laboratory, Brescia 25121, Italy.
(7) The Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
(8) Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA 

Revisão:Cell Reports

Data: 4/Abr/2017

Hematologia e Hemoterapia

The development of sensitive and non-invasive "liquid biopsies" presents new opportunities for longitudinal monitoring of tumor dissemination and clonal evolution.

The number of circulating tumor cells (CTCs) is prognostic in multiple myeloma (MM), but there is little information on their genetic features. Here, we have analyzed the genomic landscape of CTCs from 29 MM patients, including eight cases with matched/paired bone marrow (BM) tumor cells.

Our results show that 100% of clonal mutations in patient BM were detected in CTCs and that 99% of clonal mutations in CTCs were present in BM MM. These include typical driver mutations in MM such as in KRAS, NRAS, or BRAF. These data suggest that BM and CTC samples have similar clonal structures, as discordances between the two were restricted to subclonal mutations.

Accordingly, our results pave the way for potentially less invasive mutation screening of MM patients through characterization of CTCs

CITAÇÃO DO ARTIGO  Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra